Shares of Astera Labs plunged 6.1% to $219.39 on November 4, extending a brutal week-long slide from a recent $297.20, even after the AI-connectivity chipmaker delivered a quarter that beat Wall Street on every major line. The disconnect between blowout numbers and a sinking stock price raises a pointed question: has the market decided this company's explosive growth no longer justifies its price tag?

  • The Numbers Were Impressive — But the Bar Was Sky-High. Revenue hit a record $584.9 million, up 49% sequentially and 154% year-over-year, surpassing estimates of $550.8 million.

Adjusted earnings of $1.32 a share beat the $1.19 consensus.

Fourth-quarter guidance of $730–$750 million implies another 27% sequential jump — well above the prior analyst estimate of $655.8 million. Yet even those beats couldn't overcome a stock that had already priced in perfection, trading at a trailing price-to-earnings ratio of roughly 115× heading into the print.

  • Three Wall Street Firms Cut Targets in One Morning. Needham slashed its target from $425 to $300, Susquehanna dropped from $310 to $258, and Evercore ISI cut from $452 to $311 — all while keeping their ratings intact. The message: they like the business but believe the valuation got ahead of itself during the AI hype run earlier this year, when shares peaked near $499.

  • Shrinking Margins Tell a Quieter, More Worrying Story. Gross margin — the share of revenue left after manufacturing costs — fell 390 basis points year-over-year to 72.3%.

The decline was driven by higher inventory costs, manufacturing overhead, and a non-cash accounting charge tied to a warrant given to Amazon.

Management guided Q4 margins flat at around 72% , while previously suggesting a long-term target of 78% — a gap that investors are now pricing in.

  • New Revenue Drivers Are Still Years Away. Key growth catalysts — including optical networking products, custom chip designs, and a rack-scale platform — will not contribute meaningful revenue until late 2027 or 2028. Meanwhile, operating expenses are guided to $194–$200 million in Q4, reflecting a year-over-year headcount doubling. Spending is accelerating faster than margins can expand, putting pressure on the earnings trajectory investors are paying a premium for.

The bottom line: Astera Labs is growing at a pace most chipmakers would envy, but the market is recalibrating what that growth is worth — and right now, the answer is less than yesterday.